Navigation Links
Neovasc Inc. Reports Year 2008 Financial Results
Date:4/24/2009 

    --Major Actions Implemented During 2008 Position the Company for Future
    Growth--

    TSX Venture Exchange: NVC

VANCOUVER, April 24 /PRNewswire-FirstCall/ - Neovasc Inc. (TSXV: NVC), today announced financial results for the year ended December 31, 2008.

"The fundamental changes Neovasc implemented during the past year have involved hard choices, but we believe they have resulted in a lean and highly focused company that is well-positioned for the future," said Neovasc chief executive officer Alexei Marko. "We have wrung major costs out of every part of the firm, from closing facilities and reducing headcount to shelving those products and distribution channels with little chance of contributing meaningfully to near-term growth. Going forward, we are concentrating on those business segments with the greatest growth potential over the next 18 months and where we believe we can be successful without incurring significant costs. These include our tissue business, which in 2009 should benefit from our recent distribution agreement with vascular leader LeMaitre Vascular, as well as from other agreements with strategic partners that are in place or under discussion."

Mr. Marko continued, "We remain very optimistic about the clinical and commercial potential of our Reducer(TM) stent, a development stage product with the potential to revolutionize the treatment of refractory angina, which currently affects over two million patients, and we look forward to filing a CE Mark application for this important product during 2009. We continue to be proactive in seeking near-term revenue opportunities that are synergistic with our current business and that provide strong returns on investment. We believe our current businesses and our revamped strategy play to Neovasc's strengths, and we look forward to reporting on our progress over the course of the year."

Neovasc chief financial officer Chris Clark noted, "Actions
'/>"/>

SOURCE Neovasc Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine news :

1. Neovasc Reports Development Progress, Streamlined Operations and Issuance of Options
2. Neovasc Inc. Reports Third Quarter Fiscal Year 2008 Financial Results
3. Neovasc Announces Agreement With LeMaitre Vascular for Exclusive Distribution Rights to its Biological Vascular Strips
4. Neovasc Receives CE Mark Approval for Peripatch(TM) Aegis Staple Line Reinforcement Product
5. Neovasc to Raise $2 Million in Non-Brokered Private Placement
6. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
7. Haemacure Reports Third Quarter 2007 Results
8. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
9. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
10. MDS Reports Third Quarter 2007 Results
11. Allied Healthcare Reports Strong Fourth Quarter, Flat Net Income for Fiscal 2007 vs. 2006
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... May 24, 2013 CHI-California Healthcare ... and the California congressional delegation, joined by over ... industry user fees paid to the U.S. Food ... that future across-the-board cuts will not include user ... FY14 Agriculture, Rural Development and FDA Appropriations Bill. ...
(Date:5/24/2013)... FRIDAY, May 24 (HealthDay News) -- Drugs commonly used ... side effects that can interfere with vision, according to ... analogues (PGAs), which are used to reduce eye pressure, ... and changes in eye color, the researchers said, suggesting ... for PGAs. Doctors should be conservative when ...
(Date:5/24/2013)... (PRWEB) May 24, 2013 Let’s face it: ... is not uncommon for the majority of people to be ... is due to a coffee addiction or simply genetics, yellowish ... procedures are so popular. , Herald Square Dental ... very effective whitening system: Venus White Max. , Teeth ...
(Date:5/24/2013)... 24, 2013 Area homeowners dreaming about owning ... hot tubs to choose from at factory-direct pricing during the ... sales event takes place at Emerald Pool and Patio ... , Jacuzzi, the industry's leading hot tub brand, scheduled the ... country. The event will feature popular hot tub models at ...
(Date:5/24/2013)... York, New York (PRWEB) May 24, 2013 ... Vinci lawsuit involving Intuitive Surgical Inc.’s da Vinci ... According to court records, a Washington State Court jury ... committed negligence in training a surgeon who performed a ... years later. The patient’s family had alleged in ...
Breaking Medicine News(10 mins):Health News:California Biomedical Industry Leaders Urge Congress to Take Action on FDA User Fees for FY2014 2Health News:California Biomedical Industry Leaders Urge Congress to Take Action on FDA User Fees for FY2014 3Health News:Common Glaucoma Drug May Cause Droopy Eyelids, Study Finds 2Health News:Herald Square Dental Introduces New In-office Whitening System: Venus White Max 2Health News:Truckload of Jacuzzi® Hot Tubs Rolls into Bend, Oregon on May 24, 2013 for Sales Event 2Health News:Da Vinci Robot Lawsuit News: Bernstein Liebhard LLP Comments on Verdict in Nation’s First Trial Involving Alleged Da Vinci Complications 2Health News:Da Vinci Robot Lawsuit News: Bernstein Liebhard LLP Comments on Verdict in Nation’s First Trial Involving Alleged Da Vinci Complications 3
... United States Marine who lost her arm in a motorcycle accident. She ... arm that is controlled by her own nerves. ,She ... the first that she had been able to eat in a conventional ... was a very big thing for me.” ,Very often ...
... A previous survey of approximately 5,000 United Kingdom ... 34 percent of women reported habitual or regular ... gender, obesity, excessive daytime sleepiness, increasing age, night ... the upper airway. Additional studies report that some ...
... study directed by Mount Sinai School of Medicine ... regimens// might halt or even reverse symptoms of ... Attenuates Alzheimer’s Disease Type Brain Amyloidosis in Squirrel ... will be published in the November 2006 issue ...
... published in Science X-Press, an advanced, online edition of ... immunodeficiency may cause susceptibility// to herpes simplex virus. This ... how genes function in vulnerability to infections. These ... ,In the study, scientists focused on blood ...
... first international guidelines for heart failure patient management, ... for Heart and Lung Transplantation (ISHLT) has been ... Journal of Heart and Lung Transplantation. These complete ... principles failures and will guide practicing physicians and ...
... today announced an innovatory treatment for periodontal disease, that ... but also supports healing and regeneration of tissue and ... periodontal disease affects 8-12% of Americans that needs complicated ... loss, if not treated on time. ,The ...
Cached Medicine News:Health News:Bionic Women –No longer the Stuff of Science Fictio 2Health News:Prevalence of Self-reported Snoring, Sleep-disordered Breathing in Military 2Health News:Calorie Restriction May Prevent, Reduce Alzheimer’s Neuropatholog 2Health News:Genetic susceptibility in viral encephalitis 2Health News:New guidelines for global heart patient management 2Health News:New guidelines for global heart patient management 3Health News:Plastic pill – a new treatment for periodontal disease 2
(Date:5/23/2013)... de mayo de 2013  Volcano Corporation (NASDAQ: ... fabricante de herramientas de precisión para terapia guiadas ... la enfermedad vascular periférica y coronaria, anunció hoy ... enosine V asodilator I ndependent ... sesión de ensayo clínico hot line late breaking ...
(Date:5/23/2013)... OAKS, Calif. , May 23, 2013 Amgen ... Bank 38 th Annual  Healthcare Conference on Thursday, May ... Boston , beginning at 9:20 a.m. Eastern Daylight Time. ... Relations at Amgen, will present at the conference. Live audio ... on Amgen,s website, www.amgen.com , under Investors. A replay ...
(Date:5/23/2013)... RIVER EDGE, N.J. , May 23, 2013 /PRNewswire/ ... ), a commercial stage medical device company that develops ... the successful completion of its rights offering.  In addition, ... company,s March 2011 warrants expired on May 17, 2013. ... proceeds of $3.0 million from the rights offering.   A ...
Breaking Medicine Technology:Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 3Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 4Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 5Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 6Nephros Announces Completion of Rights Offering 2Nephros Announces Completion of Rights Offering 3Nephros Announces Completion of Rights Offering 4
... WILMINGTON, Del. , April 30 ... and Drug Administration (FDA) has approved VIMOVO™ ... of signs and symptoms of osteoarthritis, rheumatoid arthritis, and ... gastric ulcers in patients at risk of developing NSAID-associated ...
... The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine ... as its July 2010 "Stock to Study" and Gilead ... for investors, informational and educational use. , ... "The committee chose Teva Pharmaceutical Industries because of the tremendous ...
Cached Medicine Technology:FDA Approved VIMOVO(TM) for Arthritis Patients At Risk of Developing NSAID-Associated Gastric Ulcers 2FDA Approved VIMOVO(TM) for Arthritis Patients At Risk of Developing NSAID-Associated Gastric Ulcers 3FDA Approved VIMOVO(TM) for Arthritis Patients At Risk of Developing NSAID-Associated Gastric Ulcers 4FDA Approved VIMOVO(TM) for Arthritis Patients At Risk of Developing NSAID-Associated Gastric Ulcers 5FDA Approved VIMOVO(TM) for Arthritis Patients At Risk of Developing NSAID-Associated Gastric Ulcers 6FDA Approved VIMOVO(TM) for Arthritis Patients At Risk of Developing NSAID-Associated Gastric Ulcers 7FDA Approved VIMOVO(TM) for Arthritis Patients At Risk of Developing NSAID-Associated Gastric Ulcers 8FDA Approved VIMOVO(TM) for Arthritis Patients At Risk of Developing NSAID-Associated Gastric Ulcers 9BetterInvesting Magazine Releases July's Stock to Study and Undervalued Stock Choices for Investors' Informational and Educational Use 2BetterInvesting Magazine Releases July's Stock to Study and Undervalued Stock Choices for Investors' Informational and Educational Use 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: